http://www.biofocus.com/news.htmThe latest headlines and articles from BiofocusToday, Galapagos announced the purchase of Argenta Discovery 2009 Ltd., a privately held contract research drug discovery company with 140 employees. This company will operate under the name ‘Argenta’ as a Galapagos drug discovery service division. Together with BioFocus, the two companies will provide high quality services to the discovery research communities. The pairing-up of two profitable operations within the financially strong Galapagos Group will further maintain stability and hence credibility in the eyes of our client communities.http://www.biofocus.com/news,today-galapagos-announced-the-purchase-of-argenta-discovery-2009-ltd_114.htmTue, 02 Feb 2010 21:06:00 GMTBioFocus announced today that it has achieved success in its oncology target discovery collaboration with Ortho Biotech Oncology Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen). The success of the program has resulted in €1.6 million in target acceptance payments.http://www.biofocus.com/news,biofocus-achieves-16-m-in-payments_113.htmTue, 12 Jan 2010 14:17:00 GMTBioFocus announced today that it has signed a three year compound management agreement with the Global Alliance for TB Drug Development (TB Alliance). Under this agreement BioFocus will manage TB Alliance’s chemical library collection. These services will be provided by BioFocus’ compound management facility in South San Francisco, USA.http://www.biofocus.com/news,tb-alliance-and-biofocus-sign-compound-management-agreement_112.htmFri, 08 Jan 2010 10:18:00 GMTBioFocus, a leading provider of gene-to-drug candidate discovery services, today announced that Dr. Doris Hafenbradl has joined BioFocus as Senior Director, Biology and Natural Products, based in Basel, Switzerland.http://www.biofocus.com/news,doris-hafenbradl-joins-biofocus-as-senior-director-biology-and-natural-products_101.htmThu, 10 Dec 2009 10:43:00 GMTBioFocus® and DiscoveRx corp. announced today that they have signed a co-marketing agreement that allows BioFocus to perform screening on behalf of BioFocus’ customers using DiscoveRx PathHunter™ ß-Arrestin GPCR screening assay, HitHunter™ cAMP assays and associated cell lines.http://www.biofocus.com/news,biofocus-and-discoverx-announce-a-comarketing-agreement-for-gpcr-screening_91.htmThu, 08 Oct 2009 12:28:00 GMTBioFocus has recently launched its new microsite, www.SilenceSelect.com, dedicated to the SilenceSelect® and FLeXSelect® adenoviral technology. With the ability to knock-down or knock-in human genes in primary cells, these collections cover most of the druggable genome. Detailed information on both collections is available on the microsite, along with details of the adenovirus technology employed.http://www.biofocus.com/news,biofocus-launches-wwwsilenceselectcom-microsite_85.htmFri, 02 Oct 2009 16:05:00 GMTBioFocus, a leading provider of gene-to-drug candidate discovery services, today announced that Dr. John Nash has joined BioFocus as Senior Director, ADME/PK. John has 30 years industrial experience with both service and major pharmaceutical companies.http://www.biofocus.com/news,john-nash-joins-biofocus-as-senior-director-admepk_84.htmThu, 01 Oct 2009 00:01:00 GMTBioFocus DPI announced today that it has initiated a drug discovery collaboration with Schering-Plough Research Institute (SPRI). Under the terms of the agreement, BioFocus DPI will perform medicinal chemistry with supporting biology and ADME/PK services for multiple Schering-Plough drug discovery projects. Total contract value for BioFocus DPI is €2.8 M over a one year period.http://www.biofocus.com/news,biofocus-dpi-announces-expanded-drug-discovery-collaboration-with-scheringplough_83.htmThu, 24 Sep 2009 21:31:00 GMTBioFocus DPI, a leading provider of gene-to-drug candidate discovery services, today announced the launch of four new biologically targeted libraries. These new libraries contain novel, drug-like compounds that specifically target kinases and - for the first time - protein-protein interactions. http://www.biofocus.com/news,biofocus-dpi-launches-compound-library-targeting-proteinprotein-interactions-plus-three-new-kinase-libraries_82.htmMon, 21 Sep 2009 13:38:00 GMTBioFocus DPI announced today that it has signed a three year compound management agreement with Procter & Gamble Co. (P&G). Under the agreement, BioFocus DPI will manage P&G’s chemical library collection. These services will be provided by BioFocus DPI’s compound management facility in South San Francisco, USA.http://www.biofocus.com/news,biofocus-dpi-and-procter-gamble-sign-compound-management-agreement_80.htmWed, 12 Aug 2009 13:10:00 GMTBioFocus DPI and Oncodesign announced today that they have joined forces to offer a comprehensive oncology drug discovery service. The alliance combines BioFocus DPI’s target discovery and screening capabilities with Oncodesign’s experimental pharmacological and biomarker expertise in oncology. In addition, the partners will contribute their complementary medicinal chemistry expertise to form a drug discovery service specialized in the rapid generation of promising anticancer drug candidates.http://www.biofocus.com/news,biofocus-dpi-and-oncodesign-forge-alliance-to-provide-integrated-oncology-drug-discovery-services_79.htmMon, 27 Jul 2009 14:13:00 GMTSaffron Walden, UK; 8 July 2009 - Taking place at The Nucleus conference centre, Chesterford Research Park, Saffron Walden, UK from 22 - 23 September 2009, the new scientific conference ‘Novel Applications and Cutting Edge Technologies for GPCR Screening and Profiling’ will provide delegates with the opportunity to hear from thought leaders and share experiences within this rapidly developing field.http://www.biofocus.com/news,dates-announced-for-free-gpcr-conference_72.htmThu, 09 Jul 2009 10:16:00 GMTThe Institute for OneWorld Health, the US-based non-profit pharmaceutical company that develops drugs for people with neglected infectious diseases in the developing world, today announced that it has successfully completed its first screening campaign of the Roche proprietary compound library and will select up to 40 new drug leads for further study intended to identify a new treatment for childhood diarrhea.http://www.biofocus.com/news,institute-for-oneworld-health-announces-successful-collaboration-to-fight-neglected-diarrheal-diseases-in-developing-countries_63.htmMon, 18 May 2009 10:57:00 GMTBioFocus DPI, a leading provider of gene-to-drug candidate discovery services, today announced the launch of six new biologically targeted libraries.http://www.biofocus.com/news,biofocus-dpi-launches-six-new-softfocus-libraries_62.htmMon, 27 Apr 2009 12:30:00 GMTBioFocus DPI and TET Systems Holding announced today that they have entered into an agreement to apply TET System's inducible gene technology in high-throughput screening campaigns performed for BioFocus DPI customers.http://www.biofocus.com/news,biofocus-dpi-to-apply-tet-technology-in-highthroughput-screening-campaigns_61.htmFri, 24 Apr 2009 13:29:00 GMTBioFocus DPI announces that it has added 350,000 new compounds to its diverse screening library.http://www.biofocus.com/news,biofocus-dpi-enhances-highthroughput-screening-library_60.htmThu, 23 Apr 2009 13:26:00 GMTBioFocus DPI, a leading provider of gene-to-drug candidate discovery services, and the not-for-profit organization Medicines for Malaria Venture (MMV) announce the start of a collaboration to identify new natural product and small molecules that demonstrate anti-malarial activity.http://www.biofocus.com/news,biofocus-dpi-and-medicines-for-malaria-venture-collaborate-to-identify-antimalarial-compounds_43.htmThu, 16 Apr 2009 13:08:00 GMTHis Royal Highness the Duke of York visited Chesterford Research Park today to tour the site and meet with senior management from R&D companies based at the Park.http://www.biofocus.com/news,royal-approval-for-chesterford-research-park_1.htmFri, 03 Apr 2009 10:38:00 GMTBioFocus DPI announces that it has strengthened its ADME/PK Laboratory bioanalytical capabilities through the installation of a Waters® Xevo™ TQ Mass Spectrometer.http://www.biofocus.com/news,biofocus-dpi-enhances-admepk-laboratory-bioanalytical-capabilities_2.htmThu, 26 Feb 2009 14:08:00 GMTBioFocus DPI, the service division of Galapagos, has extended its drug discovery agreement with Eli Lilly and Company until end 2009. Under the terms of the agreement, BioFocus DPI will identify active compounds by screening of Lilly’s library compounds.http://www.biofocus.com/news,biofocus-dpi-extends-drug-discovery-collaboration-with-lilly_5.htmTue, 24 Feb 2009 09:38:00 GMT(c) 2010, Biofocus. All rights reserved.5